Literature DB >> 22879539

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Julien Haroche1, Frédéric Charlotte, Laurent Arnaud, Andreas von Deimling, Zofia Hélias-Rodzewicz, Baptiste Hervier, Fleur Cohen-Aubart, David Launay, Annette Lesot, Karima Mokhtari, Danielle Canioni, Louise Galmiche, Christian Rose, Marc Schmalzing, Sandra Croockewit, Marianne Kambouchner, Marie-Christine Copin, Sylvie Fraitag, Felix Sahm, Nicole Brousse, Zahir Amoura, Jean Donadieu, Jean-François Emile.   

Abstract

Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis. BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We investigated the frequency of BRAF mutations in several types of histiocytoses. Histology from 127 patients with histiocytoses were reviewed. Detection of BRAF(V600) mutations was performed by pyrosequencing of DNA extracted from paraffin embedded samples. Diagnoses of Erdheim-Chester disease (ECD), LCH, Rosai-Dorfman disease, juvenile xanthogranuloma, histiocytic sarcoma, xanthoma disseminatum, interdigitating dendritic cell sarcoma, and necrobiotic xanthogranuloma were performed in 46, 39, 23, 12, 3, 2, 1, and 1 patients, respectively. BRAF status was obtained in 93 cases. BRAF(V600E) mutations were detected in 13 of 24 (54%) ECD, 11 of 29 (38%) LCH, and none of the other histiocytoses. Four patients with ECD died of disease. The high frequency of BRAF(V600E) in LCH and ECD suggests a common origin of these diseases. Treatment with vemurafenib should be investigated in patients with malignant BRAF(V600E) histiocytosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22879539     DOI: 10.1182/blood-2012-05-430140

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  182 in total

Review 1.  [Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis].

Authors:  H Bösmüller; D Nann; M Horger; F Fend
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

2.  Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.

Authors:  Mrinal Gounder; Ved Desai; Deborah Kuk; Narasimhan Agaram; Maria Arcila; Benjamin Durham; Mary L Keohan; Mark A Dickson; Sandra P D'Angelo; Neerav Shukla; Craig Moskowitz; Ariela Noy; Robert G Maki; Diego Adrianzen Herrera; Armando Sanchez; Anita Krishnan; Andrew Pourmoussa; Li-Xuan Qin; William D Tap
Journal:  Eur J Cancer       Date:  2015-08-19       Impact factor: 9.162

3.  Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.

Authors:  Sergio Pina-Oviedo; L Jeffrey Medeiros; Shaoying Li; Joseph D Khoury; Keyur P Patel; Khaled Alayed; R Craig Cason; Christopher J Bowman; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

4.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Authors:  Jean-François Emile; Eli L Diamond; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; David M Hyman; Eunhee Kim; Raajit Rampal; Minal Patel; Chezi Ganzel; Shlomzion Aumann; Gladwys Faucher; Catherine Le Gall; Karen Leroy; Magali Colombat; Jean-Emmanuel Kahn; Salim Trad; Philippe Nizard; Jean Donadieu; Valérie Taly; Zahir Amoura; Omar Abdel-Wahab; Julien Haroche
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

5.  Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation.

Authors:  S Mojdeh Mirmomen; Arlene Sirajuddin; Moozhan Nikpanah; Rolf Symons; Anna K Paschall; Ioannis Papageorgiou; William A Gahl; Kevin O'Brien; Juvianee I Estrada-Veras; Ashkan A Malayeri
Journal:  Eur Radiol       Date:  2018-05-07       Impact factor: 5.315

6.  Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Authors:  Paul Milne; Venetia Bigley; Chris M Bacon; Antoine Néel; Naomi McGovern; Simon Bomken; Muzlifah Haniffa; Eli L Diamond; Benjamin H Durham; Johannes Visser; David Hunt; Harsha Gunawardena; Mac Macheta; Kenneth L McClain; Carl Allen; Omar Abdel-Wahab; Matthew Collin
Journal:  Blood       Date:  2017-05-16       Impact factor: 22.113

7.  Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation.

Authors:  Moozhan Nikpanah; Lauren Kim; S Mojdeh Mirmomen; Rolf Symons; Ioannis Papageorgiou; William A Gahl; Kevin O'Brien; Juvianee I Estrada-Veras; Ashkan A Malayeri
Journal:  Eur Radiol       Date:  2018-03-19       Impact factor: 5.315

8.  Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Authors:  Benjamin H Durham; Damien Roos-Weil; Claude Baillou; Fleur Cohen-Aubart; Akihide Yoshimi; Makoto Miyara; Matthias Papo; Zofia Hélias-Rodzewicz; Nathalie Terrones; Neval Ozkaya; Ahmet Dogan; Raajit Rampal; Fanny Urbain; Lucie Le Fèvre; Eli L Diamond; Christopher Y Park; Thomas Papo; Frédéric Charlotte; Guy Gorochov; Valérie Taly; Olivier A Bernard; Zahir Amoura; Omar Abdel-Wahab; François M Lemoine; Julien Haroche; Jean-François Emile
Journal:  Blood       Date:  2017-05-31       Impact factor: 22.113

9.  The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease.

Authors:  Greta Pacini; Giulio Cavalli; Alessandro Tomelleri; Giacomo De Luca; Guido Pacini; Marina Ferrarini; Claudio Doglioni; Lorenzo Dagna
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

10.  Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.

Authors:  Elisabetta Ferrero; Angelo Corti; Julien Haroche; Daniela Belloni; Barbara Colombo; Alvise Berti; Giulio Cavalli; Corrado Campochiaro; Antonello Villa; Fleur Cohen-Aubart; Zahir Amoura; Claudio Doglioni; Lorenzo Dagna; Marina Ferrarini
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.